Search

Your search keyword '"Hiroki Itoh"' showing total 8 results
Start Over Author "Hiroki Itoh" Journal clinical case reports
8 results on '"Hiroki Itoh"'

1. Significant elevation of free itraconazole concentration at onset of adverse effects: A case report

Author

Ryota Tanaka, Yosuke Suzuki, Hiroyuki Matsumoto, Mari Yamasue, Kenji Umeki, Kazuhiko Hashinaga, Ryosuke Tatsuta, Kazufumi Hiramatsu, Katsuhiko Kamei, Jun‐ichi Kadota, and Hiroki Itoh

Subjects
adverse effects, free concentration, hydroxyitraconazole, Itraconazole, therapeutic drug monitoring, Medicine, Medicine (General), R5-920
Abstract

Abstract Free itraconazole and hydroxyitraconazole concentrations were markedly elevated despite almost no changes in total concentrations when itraconazole was discontinued due to adverse effects. Elevated free itraconazole concentration may have a causal relationship with the development of adverse effects.

Published
2021
Full Text
View/download PDF

2. Effect of S‐1 on blood levels of phenobarbital and phenytoin: A case report

Author

Ken Shiraiwa, Hiroyuki Ono, Ryota Tanaka, Atsuro Fujinaga, Takahiro Hiratsuka, Ryosuke Tatsuta, Masafumi Inomata, and Hiroki Itoh

Subjects
drug‐drug interaction, phenobarbital, phenytoin, S‐1, therapeutic drug monitoring, Medicine, Medicine (General), R5-920
Abstract

Abstract Drug‐drug interaction of fluorinated pyrimidine anticancer agents with phenytoin is well known, but interaction with phenobarbital is limited. We describe a case showing increases in plasma phenobarbital as well as phenytoin concentrations during preoperative S‐1 (tegafur/gimeracil/oteracil) and radiation therapy for rectal cancer.

Published
2021
Full Text
View/download PDF

3. Sustained suppression of enterohepatic circulation of mycophenolic acid by antimicrobial‐associated diarrhea in a kidney transplant recipient with Crohn's disease: A case report

Author

Ryota Tanaka, Asami Matsumoto, Ryosuke Tatsuta, Tadasuke Ando, Toshitaka Shin, Hiromitsu Mimata, and Hiroki Itoh

Subjects
antimicrobial‐associated diarrhea, broad‐spectrum antibiotics, enterohepatic circulation, mycophenolic acid, Medicine, Medicine (General), R5-920
Abstract

Abstract Mycophenolic acid (MPA) undergoes enterohepatic circulation. A kidney transplant patient on mycophenolate mofetil was treated with tazobactam/piperacillin for pyelonephritis, and developed antimicrobial‐associated diarrhea. Consequently, the MPA trough level decreased by approximately 90%. Furthermore, it took approximately a month for the MPA level to normalize even after diarrhea had resolved.

Published
2022
Full Text
View/download PDF

4. Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction

Author

Ryosuke Nakahara, Takahiro Sumimoto, Ryota Tanaka, Masao Ogata, and Hiroki Itoh

Subjects
acute renal dysfunction, chronic myeloid leukemia, dialysis, Imatinib, therapeutic drug monitoring, Medicine, Medicine (General), R5-920
Abstract

Abstract Fixed dose regimen is currently the standard administration method for TKI. However, this case report indicated that TDM may by a useful approach to individualized dosing of TKI for the treatment of CML when initiating dialysis.

Published
2021
Full Text
View/download PDF

5. Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report

Author

Ryosuke Nakahara, Takahiro Sumimoto, Masao Ogata, Yuhki Sato, and Hiroki Itoh

Subjects
chronic myeloid leukemia, hepatic dysfunction, nilotinib, therapeutic drug monitoring, Medicine, Medicine (General), R5-920
Abstract

Abstract Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individualized dosing of TKI for the treatment of CML.

Published
2019
Full Text
View/download PDF

6. Effect of S‐1 on blood levels of phenobarbital and phenytoin: A case report

Author

Masafumi Inomata, Atsuro Fujinaga, Ryosuke Tatsuta, Ken Shiraiwa, Hiroki Itoh, Hiroyuki Ono, Ryota Tanaka, and Takahiro Hiratsuka

Subjects
Phenytoin, Colorectal cancer, medicine.medical_treatment, therapeutic drug monitoring, Drug-drug interaction, lcsh:Medicine, Case Report, Case Reports, phenobarbital, 030204 cardiovascular system & hematology, Pharmacology, Tegafur, 03 medical and health sciences, 0302 clinical medicine, drug‐drug interaction, medicine, otorhinolaryngologic diseases, lcsh:R5-920, medicine.diagnostic_test, S‐1, business.industry, lcsh:R, phenytoin, General Medicine, medicine.disease, Radiation therapy, stomatognathic diseases, Therapeutic drug monitoring, 030220 oncology & carcinogenesis, Phenobarbital, business, lcsh:Medicine (General), medicine.drug
Abstract

Drug‐drug interaction of fluorinated pyrimidine anticancer agents with phenytoin is well known, but interaction with phenobarbital is limited. We describe a case showing increases in plasma phenobarbital as well as phenytoin concentrations during preoperative S‐1 (tegafur/gimeracil/oteracil) and radiation therapy for rectal cancer., When used in combination with a fluorinated pyrimidine anticancer drug such as S‐1, the blood level of PB as well as PHT may increase. In order to avoid adverse events due to this interaction, confirmation for the blood levels of PHT and PB by TDM is essential.

Published
2021

7. Significant elevation of free itraconazole concentration at onset of adverse effects: A case report

Author

Kenji Umeki, Yosuke Suzuki, Jun-ichi Kadota, Ryota Tanaka, Kazufumi Hiramatsu, Hiroki Itoh, Mari Yamasue, Ryosuke Tatsuta, Kazuhiko Hashinaga, Hiroyuki Matsumoto, and Katsuhiko Kamei

Subjects
Itraconazole, therapeutic drug monitoring, lcsh:Medicine, Case Report, Case Reports, 030204 cardiovascular system & hematology, Pharmacology, Significant elevation, 03 medical and health sciences, 0302 clinical medicine, medicine, Adverse effect, free concentration, hydroxyitraconazole, lcsh:R5-920, medicine.diagnostic_test, business.industry, lcsh:R, General Medicine, Therapeutic drug monitoring, 030220 oncology & carcinogenesis, adverse effects, lcsh:Medicine (General), business, medicine.drug
Abstract

Free itraconazole and hydroxyitraconazole concentrations were markedly elevated despite almost no changes in total concentrations when itraconazole was discontinued due to adverse effects. Elevated free itraconazole concentration may have a causal relationship with the development of adverse effects.

Published
2021

8. Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction

Author

Hiroki Itoh, Takahiro Sumimoto, Ryosuke Nakahara, Masao Ogata, and Ryota Tanaka

Subjects
Oncology, medicine.medical_specialty, medicine.diagnostic_test, Individualized dosing, business.industry, therapeutic drug monitoring, medicine.medical_treatment, acute renal dysfunction, Myeloid leukemia, Case Report, Imatinib, Case Reports, General Medicine, Fixed dose, respiratory tract diseases, Regimen, chronic myeloid leukemia, Therapeutic drug monitoring, Internal medicine, medicine, dialysis, business, Dialysis, medicine.drug
Abstract

Fixed dose regimen is currently the standard administration method for TKI. However, this case report indicated that TDM may by a useful approach to individualized dosing of TKI for the treatment of CML when initiating dialysis.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results